CA2721200A1 - Methods of screening for compounds that inhibit the biosynthesis of gpi in malaria parasites - Google Patents

Methods of screening for compounds that inhibit the biosynthesis of gpi in malaria parasites Download PDF

Info

Publication number
CA2721200A1
CA2721200A1 CA2721200A CA2721200A CA2721200A1 CA 2721200 A1 CA2721200 A1 CA 2721200A1 CA 2721200 A CA2721200 A CA 2721200A CA 2721200 A CA2721200 A CA 2721200A CA 2721200 A1 CA2721200 A1 CA 2721200A1
Authority
CA
Canada
Prior art keywords
protein
gpi
gwt1
dna
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2721200A
Other languages
English (en)
French (fr)
Inventor
Katsura Hata
Kaoru Ogawa
Itaru Tsukada
Kazutaka Nakamoto
Koji Sagane
Keigo Tanaka
Kappei Tsukahara
Toshihiro Horii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of CA2721200A1 publication Critical patent/CA2721200A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
    • G01N2333/445—Plasmodium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2721200A 2002-11-22 2003-11-21 Methods of screening for compounds that inhibit the biosynthesis of gpi in malaria parasites Abandoned CA2721200A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42858902P 2002-11-22 2002-11-22
US60/428,589 2002-11-22
CA2505067A CA2505067C (en) 2002-11-22 2003-11-21 Methods of screening for compounds that inhibit the biosynthesis of gpi in malaria parasites

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2505067A Division CA2505067C (en) 2002-11-22 2003-11-21 Methods of screening for compounds that inhibit the biosynthesis of gpi in malaria parasites

Publications (1)

Publication Number Publication Date
CA2721200A1 true CA2721200A1 (en) 2004-06-10

Family

ID=32393427

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2721200A Abandoned CA2721200A1 (en) 2002-11-22 2003-11-21 Methods of screening for compounds that inhibit the biosynthesis of gpi in malaria parasites
CA2704070A Abandoned CA2704070A1 (en) 2002-11-22 2003-11-21 Methods of screening for compounds that inhibit the biosynthesis of gpi in malaria parasites
CA2505067A Expired - Fee Related CA2505067C (en) 2002-11-22 2003-11-21 Methods of screening for compounds that inhibit the biosynthesis of gpi in malaria parasites

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2704070A Abandoned CA2704070A1 (en) 2002-11-22 2003-11-21 Methods of screening for compounds that inhibit the biosynthesis of gpi in malaria parasites
CA2505067A Expired - Fee Related CA2505067C (en) 2002-11-22 2003-11-21 Methods of screening for compounds that inhibit the biosynthesis of gpi in malaria parasites

Country Status (9)

Country Link
US (2) US7928215B2 (ja)
EP (1) EP1565749B9 (ja)
JP (3) JP4315907B2 (ja)
KR (4) KR100933759B1 (ja)
CN (3) CN101092627B (ja)
AT (1) ATE525654T1 (ja)
AU (1) AU2003282393B2 (ja)
CA (3) CA2721200A1 (ja)
WO (1) WO2004048567A2 (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03000177A (es) * 2000-07-07 2004-09-13 Eisai Co Ltd Gen de sintesis de la pared celula fungal.
EP1564299B1 (en) * 2002-11-22 2007-06-20 Eisai R&D Management Co., Ltd. Method of screening for compounds that inhibit the enzymatic activity of gwt1 gene product
US7932272B2 (en) 2003-09-30 2011-04-26 Eisai R&D Management Co., Ltd. Antifungal agent containing heterocyclic compound
EP1782811A4 (en) 2004-08-09 2010-09-01 Eisai R&D Man Co Ltd INNOVATIVE ANTIPALUDITIC AGENT CONTAINING A HETEROCYCLIC COMPOUND
US7829585B2 (en) 2005-03-30 2010-11-09 Eisai R&D Management Co., Ltd. Antifungal agent containing pyridine derivative
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
EP2065377B1 (en) 2006-09-21 2011-11-23 Eisai R&D Management Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
JP5354542B2 (ja) * 2007-09-14 2013-11-27 国立大学法人 長崎大学 熱帯熱マラリアワクチン候補分子
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
US8188119B2 (en) 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
PE20131412A1 (es) 2010-08-03 2014-01-19 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2013192517A2 (en) * 2012-06-21 2013-12-27 Whitehead Institute For Biomedical Research Compounds for treating infectious diseases
KR102063576B1 (ko) * 2012-07-24 2020-01-10 한국전자통신연구원 가상화 기반 은닉형 소프트웨어 실행 환경 제공 방법 및 장치
KR101954733B1 (ko) * 2012-10-26 2019-03-06 삼성전자주식회사 보안 콘텐츠를 처리하는 시스템 온 칩 및 그것을 포함하는 모바일 장치
CN109825514A (zh) * 2019-01-24 2019-05-31 华中农业大学 田鼠巴贝斯虫gpi10基因及其编码的蛋白和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19640817A1 (de) 1996-10-02 1998-05-14 Hermann Prof Dr Bujard Rekombinantes Herstellungsverfahren für ein vollständiges Malaria-Antigen gp190/MSP 1
WO1999021986A1 (en) 1997-10-29 1999-05-06 Shanghai Second Medical University Cbfbga09: a human sl15 homolog
AU2392300A (en) 1998-12-31 2000-07-31 Millennium Pharmaceuticals, Inc. Use of essential (saccharomyces) genes and polypeptides
WO2001013923A1 (en) * 1999-08-20 2001-03-01 Georgetown University Malaria gpi anchors as vaccines anti-parasitic drugs and for use in diagnostics
CN100467597C (zh) 2000-07-07 2009-03-11 卫材R&D管理有限公司 真菌细胞壁合成基因
MXPA03000177A (es) 2000-07-07 2004-09-13 Eisai Co Ltd Gen de sintesis de la pared celula fungal.
EP1346049B1 (en) 2000-12-22 2012-08-01 Stichting Biomedical Primate Research Centre Efficient expression of plasmodium apical membrane antigen 1 in yeast cells
DE10254397B4 (de) 2002-11-21 2010-09-23 Poloplast Gmbh & Co. Kg Universalschlauchkupplung
EP1564299B1 (en) 2002-11-22 2007-06-20 Eisai R&D Management Co., Ltd. Method of screening for compounds that inhibit the enzymatic activity of gwt1 gene product

Also Published As

Publication number Publication date
ATE525654T1 (de) 2011-10-15
KR20070010088A (ko) 2007-01-19
CN101092627B (zh) 2011-08-17
JP2006506996A (ja) 2006-03-02
EP1565749B1 (en) 2011-09-21
US7928215B2 (en) 2011-04-19
CN101092628B (zh) 2010-11-03
EP1565749A2 (en) 2005-08-24
CN101092627A (zh) 2007-12-26
US20060172404A1 (en) 2006-08-03
CA2704070A1 (en) 2004-06-10
JP4376297B2 (ja) 2009-12-02
KR100825547B1 (ko) 2008-04-25
CN101092628A (zh) 2007-12-26
US8252294B2 (en) 2012-08-28
US20110201816A1 (en) 2011-08-18
EP1565749B9 (en) 2012-04-25
KR100933759B1 (ko) 2009-12-23
CN100504392C (zh) 2009-06-24
WO2004048567A2 (en) 2004-06-10
KR20070065452A (ko) 2007-06-22
CA2505067C (en) 2011-08-02
JP4315907B2 (ja) 2009-08-19
AU2003282393B2 (en) 2007-07-05
KR20050085105A (ko) 2005-08-29
CN1742203A (zh) 2006-03-01
WO2004048567A3 (en) 2004-10-14
CA2505067A1 (en) 2004-06-10
KR20100039428A (ko) 2010-04-15
AU2003282393A1 (en) 2004-06-18
JP2009077715A (ja) 2009-04-16
JP2009183290A (ja) 2009-08-20

Similar Documents

Publication Publication Date Title
US8252294B2 (en) Methods of screening for compounds that inhibit the biosynthesis of GPI in malaria parasites
Fillinger et al. cAMP and ras signalling independently control spore germination in the filamentous fungus Aspergillus nidulans
Mouyna et al. Members of protein O‐mannosyltransferase family in Aspergillus fumigatus differentially affect growth, morphogenesis and viability
Darsow et al. A multispecificity syntaxin homologue, Vam3p, essential for autophagic and biosynthetic protein transport to the vacuole
Kaffman et al. Phosphorylation regulates association of the transcription factor Pho4 with its import receptor Pse1/Kap121
Arellano et al. Schizosaccharomyces pombe protein kinase C homologues, pck1p and pck2p, are targets of rho1p and rho2p and differentially regulate cell integrity
Watanabe et al. E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis
Trilla et al. Chs7p, a new protein involved in the control of protein export from the endoplasmic reticulum that is specifically engaged in the regulation of chitin synthesis in Saccharomyces cerevisiae
Komachi et al. gfsA encodes a novel galactofuranosyltransferase involved in biosynthesis of galactofuranose antigen of O‐glycan in A spergillus nidulans and A spergillus fumigatus
Ichinomiya et al. Class I and class II chitin synthases are involved in septum formation in the filamentous fungus Aspergillus nidulans
García-Muse et al. Characterization of B-type cyclins in the smut fungus Ustilago maydis: roles in morphogenesis and pathogenicity
CA2251593A1 (en) Assays and reagents for identifying anti-fungal agents, and uses related thereto
Tay et al. Study of Plasmodium falciparum DHHC palmitoyl transferases identifies a role for PfDHHC9 in gametocytogenesis
Jochum et al. Yeast Ysl2p, homologous to Sec7 domain guanine nucleotide exchange factors, functions in endocytosis and maintenance of vacuole integrity and interacts with the Arf-Like small GTPase Arl1p
Bandini et al. The nucleocytosolic O-fucosyltransferase Spindly affects protein expression and virulence in Toxoplasma gondii
Pérez-Sánchez et al. Interaction of the heterotrimeric G protein alpha subunit SSG-1 of Sporothrix schenckii with proteins related to stress response and fungal pathogenicity using a yeast two-hybrid assay
AU2007216681B2 (en) Methods of screening for compounds that inhibit the biosynthesis of GPI in malaria parasites
Parrish et al. PtdIns (3) P accumulation in triple lipid-phosphatase-deletion mutants triggers lethal hyperactivation of the Rho1p/Pkc1p cell-integrity MAP kinase pathway
Guo et al. A broadly active fucosyltransferase LmjFUT1 whose mitochondrial localization and catalytic activity is essential in parasitic Leishmania major
WO2003074728A2 (en) Screening for modulators of pkng activity
WO2004048604A1 (ja) Gwt1遺伝子産物の酵素活性を阻害する化合物をスクリーニングする方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20131121